How to Test for Mast Cell Activation Syndrome (MCAS)

Testing for mast cell activation syndrome involves meeting three criteria: having typical episodic symptoms (flushing, abdominal cramping, low blood pressure, hives, or anaphylaxis-type reactions), showing a measurable rise in a blood marker called tryptase during an episode compared to your personal baseline, and seeing improvement with medications that target mast cell chemicals.¹ All three legs of this triad matter, and none on its own is enough. The process sounds straightforward on paper, but in practice it is one of the more frustrating diagnostic journeys in medicine, largely because the timing of blood draws, the choice of lab tests, and even which set of diagnostic rules your doctor follows can change whether you get a diagnosis.

The Three-Legged Diagnostic Triad

The most widely referenced framework for diagnosing MCAS was published by an international consensus group in 2012 and requires all three of the following: recurrent episodes of mast cell activation symptoms affecting at least two organ systems, a documented rise in serum tryptase during or shortly after an episode compared to the patient’s own baseline, and clinical improvement with therapies aimed at mast cell mediators (antihistamines, mast cell stabilizers, or leukotriene blockers).² The symptom piece is the easiest to demonstrate because most people seeking testing already have a long list of multisystem complaints. The trickier parts are catching the biochemical evidence and then confirming that treatment actually helps.

A competing set of criteria, sometimes called “consensus-2,” is broader. It still requires symptoms and treatment response, but it allows a wider range of lab abnormalities beyond tryptase and applies less strict thresholds. Some researchers favor it because the stricter criteria may miss patients whose mast cells are genuinely misbehaving but whose tryptase never spikes high enough to cross the bar. The debate is not settled: one camp argues that the broader criteria risk overdiagnosis, while the other contends that underdiagnosis by the stricter rules is the bigger problem given estimates that MCAS may affect a sizable portion of the general population.³ The practical takeaway for you: the criteria your doctor uses will shape which tests are ordered and how the results are interpreted, so it is worth asking which framework they follow.

The Tryptase Test and the “20% + 2” Formula

Tryptase is a protein released by mast cells when they degranulate. It is the single most accepted blood marker of a mast cell activation event, and it is central to the stricter diagnostic criteria. But simply having a high tryptase level is not enough. What matters is the rise from your own personal baseline. Your baseline tryptase varies depending on genetics, age, kidney function, and whether you have an underlying mast cell disease, so a number that is abnormal for one person might be perfectly normal for another.²

The consensus formula works like this: during an episode, your peak tryptase should exceed 120% of your baseline value plus 2 ng/mL. So if your baseline tryptase sits at 5 ng/mL, the episode sample would need to be above 8 ng/mL (1.2 × 5 + 2) to count. This formula has been validated by independent groups and performs well across low, normal, and elevated baseline ranges.⁴ In a validation study looking at perioperative anaphylaxis, the formula showed a specificity of 91% and a positive predictive value of 98%, meaning that when the test says an activation event happened, it almost always did. Its sensitivity was more moderate at 78%, and the negative predictive value was 44%, which means a normal result does not rule out mast cell activation.⁵

The timing of the blood draw is critical. Tryptase peaks roughly 15 minutes to an hour after a severe episode and then clears from the blood within a few hours. Most guidelines call for the acute sample to be drawn within four hours of the episode’s onset. You also need a baseline sample taken when you are symptom-free, ideally at least 24 hours after any flare. Without both numbers, the formula cannot be applied.² This is where many patients hit a wall: episodes are unpredictable, and getting to a lab or emergency room quickly enough to catch the tryptase peak is logistically hard, especially if episodes happen at night or in settings far from a blood-draw facility.

Urine Tests for Mast Cell Mediators

Because catching a tryptase spike is so time-sensitive, urine tests offer an alternative way to document mast cell activation. Mast cells release more than just tryptase. They also release prostaglandins, histamine, and leukotrienes. The breakdown products of these chemicals can be measured in urine collected over a 24-hour period or in a spot collection timed to follow an episode.

In a cohort study of 25 patients with suspected MCAS, urinary 11β-prostaglandin F2α was the most frequently elevated mediator. Serum tryptase was elevated in 10 of those patients, while urinary N-methylhistamine was elevated in only 2, suggesting that histamine metabolites in urine may be less helpful for making the diagnosis.⁶ This is why many specialists order prostaglandin metabolites alongside tryptase rather than relying on a single test. Urinary leukotriene E4 is another mediator that some centers add to the panel.

Canadian clinical guidance recommends comparing urine mediator levels obtained during a flare (collected roughly three to six hours after the event) with a baseline sample collected during a symptom-free period. A single elevated baseline value is not diagnostic of MCAS, nor does a single normal value exclude it. The pattern of rise and fall matters more than any isolated number.⁷

Urine collections come with their own hassles. The 24-hour collection must be refrigerated throughout, and certain foods, medications, and supplements can interfere with results. NSAIDs, for example, alter prostaglandin metabolism, and antihistamines can suppress histamine metabolite levels. Your doctor should give you a list of what to avoid beforehand, and ideally the collection should happen during a flare while you are off interfering medications, though stopping medications is not always safe or practical.

Why the Tests Miss People

The moderate sensitivity of the tryptase formula and the logistical challenges of timed collections mean that a substantial number of people with genuine MCAS will produce normal lab work. This does not always mean the condition is absent. Tryptase is best at detecting severe, systemic mast cell activation events like anaphylaxis. Milder or more localized episodes, where mast cells degranulate predominantly in the gut or skin rather than flooding the bloodstream, may not produce a tryptase rise large enough to meet the formula’s threshold. The validation study’s negative predictive value of 44% underscores this gap: more than half of people with a negative tryptase result during an episode may still have had mast cell activation.⁵

This is one reason the broader “consensus-2” approach exists. Proponents argue that requiring a documented tryptase spike sets an impossibly high bar for patients whose symptoms are real but whose biology does not cooperate with the test’s timing or sensitivity constraints. Critics counter that loosening the criteria risks labeling common, nonspecific symptoms as MCAS, leading to inappropriate treatment and missed alternative diagnoses.¹ In practical terms, if your first round of testing comes back normal but your symptoms are convincing, many specialists will repeat the tests during a subsequent episode or add urine mediators that were not initially checked.

Tissue Biopsies and What They Can (and Cannot) Show

Some patients undergo tissue biopsies, usually from the gastrointestinal tract, skin, or bone marrow, as part of the workup. In systemic mastocytosis, a related but distinct condition, biopsies show clusters of abnormal mast cells that stain positive for specific surface markers like CD25. In a study of GI biopsies from patients with systemic mastocytosis, researchers found that mast cell involvement in the gut is often subtle and frequently accompanied by prominent eosinophils that can obscure the mast cell infiltrate. Staining for KIT and CD25 proved invaluable for making the diagnosis in those cases.⁸

For MCAS specifically, though, biopsies are less clear-cut. A 2025 study that quantified mast cells across different conditions found that mast cell numbers were elevated in MCAS, systemic mastocytosis, and inflammatory disorders alike compared to healthy tissue. The study also assessed the “tryptase depletion index,” a measure of how much tryptase has been released from mast cells in tissue, and found it did not differ meaningfully among the groups. Statistical analysis showed low sensitivity and specificity for both mast cell counts and the tryptase depletion index when used to diagnose MCAS.⁹ In other words, a biopsy can help rule in or rule out mastocytosis, but it is not a reliable standalone tool for confirming MCAS.

Ruling Out Mastocytosis and Other Causes

Before settling on an MCAS diagnosis, your doctor needs to exclude conditions that look similar. The most important one to rule out is systemic mastocytosis, where mast cells carry a specific mutation called KIT D816V and accumulate abnormally in the bone marrow and other tissues. Mastocytosis is diagnosed according to World Health Organization criteria and is a clonal disorder, meaning the mast cells are genetically abnormal.¹⁰ Testing for the KIT D816V mutation can be done on peripheral blood using highly sensitive molecular assays, and a bone marrow biopsy may follow if clinical suspicion is high.

MCAS itself falls into subtypes based on what is driving the mast cell misbehavior. Primary MCAS involves mast cells that carry the KIT mutation but do not meet full criteria for mastocytosis. Secondary MCAS results from an identifiable trigger such as IgE-mediated allergy or another reactive condition that provokes mast cell degranulation. Idiopathic MCAS is diagnosed when neither a clonal abnormality nor a triggering condition can be found.¹¹ These distinctions matter for treatment: primary MCAS may benefit from therapies targeting the clonal mast cells, while secondary MCAS resolves if the underlying trigger is addressed.

Another condition that can muddy the diagnostic picture is hereditary alpha-tryptasemia, a genetic trait caused by extra copies of the TPSAB1 gene. It affects an estimated 4 to 6% of the Western population and is the most common cause of a persistently elevated baseline tryptase.¹² People with this trait can have symptoms that overlap with MCAS, including flushing, itching, gut dysfunction, and connective tissue abnormalities, but their elevated tryptase is constitutional rather than episodic. Testing for extra TPSAB1 copies can be done through specialized genetic labs and is increasingly considered a routine part of the MCAS workup when baseline tryptase is elevated.

The Treatment-Response Criterion

The third leg of the diagnostic triad, response to mast cell-targeted therapy, often gets treated as an afterthought but is formally required under the stricter consensus criteria. Your doctor will typically start with over-the-counter H1 antihistamines (like cetirizine or loratadine), add an H2 antihistamine (like famotidine), and possibly layer on a mast cell stabilizer such as cromolyn sodium or a leukotriene receptor antagonist like montelukast. If your symptoms improve substantially on this regimen, that counts as supporting evidence for the diagnosis.¹

This criterion is both a strength and a weakness of the diagnostic framework. On one hand, it prevents the diagnosis from resting solely on lab numbers that can be noisy or hard to obtain. On the other hand, antihistamines improve symptoms in plenty of conditions that are not MCAS, so a positive response is not specific. Experts who emphasize the importance of using strict criteria have warned that increasing numbers of patients are receiving an MCAS diagnosis based on nonspecific criteria, and that this misdiagnosis can distract from finding the real cause of symptoms.¹³

Testing in Children

Diagnosing MCAS in children adds layers of complexity. Pediatric reference ranges for mast cell mediators are not as well established as adult ranges, and children are less able to describe the subjective experience of symptoms like brain fog or presyncope. In a retrospective study of a pediatric cohort, 32 patients had at least one elevated urine mast cell mediator based on adult reference intervals. Of those, only six (6%) met criteria for MCAS, while five had forms of mastocytosis. The average age at diagnosis was 9 years. Two children whose initial baseline testing was normal were later diagnosed after serial testing caught elevated prostaglandin D2 or leukotriene E4 during a symptomatic episode.¹⁴ The takeaway for parents pursuing a diagnosis: repeated testing around the time of flares, rather than a single snapshot, may be necessary to catch abnormalities.

The Overlap With POTS and Ehlers-Danlos Syndrome

If you are being evaluated for MCAS, there is a reasonable chance you have also heard of postural orthostatic tachycardia syndrome (POTS) or Ehlers-Danlos syndrome (EDS), because the three conditions frequently travel together. A study comparing patients with both POTS and EDS to patients with neither condition found that 31% of the POTS-plus-EDS group also met criteria for MCAS, compared to 2% of the group without those conditions. The odds ratio was about 32, meaning the co-occurrence was far beyond what chance would predict.¹⁵

Why these conditions cluster is still poorly understood. Proposed explanations range from shared connective tissue abnormalities that affect the tissue environment where mast cells live, to autonomic nervous system dysfunction that lowers the threshold for mast cell degranulation. From a testing perspective, the overlap means that if you have POTS or EDS and unexplained flushing, GI distress, or recurrent near-anaphylaxis, your doctor should at least consider MCAS in the differential. It also means that symptom checklists alone are unreliable in this population, since POTS itself causes many symptoms that mimic mast cell activation (palpitations, lightheadedness, GI motility problems). Lab confirmation becomes especially important to avoid attributing every symptom to a single diagnosis.

Emerging Tools on the Horizon

Several research groups are working on flow cytometry-based tests that measure how activated basophils and mast cells are after being exposed to a suspected trigger in a test tube. The basophil activation test (BAT) has accumulated evidence supporting its use in IgE-dependent allergies and drug hypersensitivities, and a mast cell activation test (MAT) is in earlier stages of development.¹⁶ The idea is appealing: rather than trying to catch a tryptase spike in real time, you could stimulate the patient’s cells in a controlled lab setting and watch what happens.

The practical barriers remain high, though. The BAT requires fresh whole blood analyzed within 4 to 24 hours, making batch processing and comparison across laboratories difficult. There is no standardization of the allergen sources, concentrations, reagents, or markers used. And roughly 10 to 15% of people tested show a “nonresponder” pattern, meaning their basophils simply do not activate in the test tube regardless of the stimulus, rendering the test uninterpretable.¹⁷ For now, these tests remain research tools rather than routine clinical options, but they represent the most promising avenue for improving diagnostic accuracy in the next decade.

A Practical Checklist for Getting Tested

If you suspect MCAS and want to approach the diagnostic process efficiently, a few practical steps can make the difference between useful results and wasted effort:

Establish a baseline: Get a serum tryptase level drawn during a symptom-free period. This number is the denominator in the formula, and without it, an acute draw is hard to interpret.
Plan for the acute draw: Talk to your doctor about a standing lab order so you can go directly to a lab or ER during an episode. The blood needs to be drawn within four hours of symptom onset, and sooner is better.
Collect urine strategically: Ask about a 24-hour urine collection for prostaglandin D2 metabolites and leukotriene E4, timed to coincide with a flare period. A baseline 24-hour collection during a calm period provides the comparison.
Hold medications when safe: NSAIDs, aspirin, and antihistamines can alter mediator levels. Your doctor can advise which to pause before testing and for how long.
Expect repeat testing: A single normal result does not close the door. If episodes continue, testing during a different flare or adding mediators not previously checked is reasonable.
Screen for mimics: Baseline tryptase above the upper reference range should prompt consideration of hereditary alpha-tryptasemia testing and, if clinical suspicion warrants it, evaluation for systemic mastocytosis.

The frustration many patients feel is not a failure of effort but a reflection of the biology: mast cell mediators are transient, lab infrastructure is not built for urgent specimen handling, and the diagnostic criteria remain a work in progress. The field is genuinely difficult, and even specialists disagree about where to draw the line between disease and normal variation. Persistence and a systematic approach to timed specimen collection remain your best tools while the science catches up.